Developer and marketer of novel, small molecule drugs for the treatment of cardiovascular diseases. The company's major products were Ranexa (ranolazine extended-release tablets) and Lexiscan (regadenoson).
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
9. Merger/Acquisition | 17-Apr-2009 | $1.4B | 00000 | 00.00 | Completed | Generating Revenue |
8. PIPE | 16-Apr-2008 | 00000 | 00000 | Completed | Generating Revenue | |
7. PIPE | 18-Apr-2006 | 00000 | 00000 | Completed | Generating Revenue | |
6. PIPE | 01-Aug-2000 | 00000 | 00000 | Completed | Generating Revenue | |
5. IPO | 06-Oct-1999 | 0000 | 00000 | Completed | Generating Revenue | |
4. Later Stage VC (Series G) | 01-May-1996 | 000.00 | 000.00 | Completed | Generating Revenue | |
3. Later Stage VC (Series E) | 01-Nov-1995 | 00.000 | 000.00 | Completed | Generating Revenue | |
2. Later Stage VC (Series D) | 01-Apr-1994 | $16.5M | $23.4M | Completed | Generating Revenue | |
1. Later Stage VC (Series C) | 01-Jul-1993 | $6.88M | $6.88M | Completed | Generating Revenue |
Growth Rate
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Acqua Wellington | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Alloy Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Asset Management Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Axon Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Azimuth Opportunity | Investment Bank | Minority | 000 0000 | 000000 0 |